forebear
发表于 2025-3-26 23:18:14
Abbildungen, reelle Funktionen,itro and in vivo. Here we provide a robust protocol for the synthesis of triple GalNAc CPG solid support and GalNAc phosphoramidite, synthesis and purification of RNA conjugates with multiple GalNAc residues either to 5′-end or 3′-end and siRNA duplex formation.
笨拙的我
发表于 2025-3-27 01:19:19
Wilfried Plaßmann,Detlef Schulz stability of the siRNA/NV ensemble; (3) characterization and quantification of the cellular uptake and release of the siRNA fragment; (4) in vitro and (5) in vivo experiments for the evaluation of the corresponding gene silencing activity; and (6) assessment of the intrinsic toxicity of the NV and the siRNA/NV complex.
Adulate
发表于 2025-3-27 06:02:21
http://reply.papertrans.cn/27/2686/268543/268543_33.png
欢笑
发表于 2025-3-27 11:19:27
http://reply.papertrans.cn/27/2686/268543/268543_34.png
overrule
发表于 2025-3-27 15:39:13
http://reply.papertrans.cn/27/2686/268543/268543_35.png
失眠症
发表于 2025-3-27 20:46:51
http://reply.papertrans.cn/27/2686/268543/268543_36.png
aesthetician
发表于 2025-3-28 00:34:20
Development of siRNA Therapeutics for the Treatment of Liver Diseases,nd givosiran for the treatment of acute hepatic porphyria, respectively. Here, we describe the current strategies for delivering siRNA drugs to the liver and summarize recent advances in clinical development of siRNA therapeutics for the treatment of liver diseases.
发生
发表于 2025-3-28 05:45:30
siRNA Design and GalNAc-Empowered Hepatic Targeted Delivery,lity and reduce its off-target effect. Also, the delivery method based on .-acetylgalactosamine (GalNAc)-siRNA conjugate that is widely employed to develop therapeutic regimens for liver-related diseases is also recapitulated.
手铐
发表于 2025-3-28 06:48:36
http://reply.papertrans.cn/27/2686/268543/268543_39.png
FORGO
发表于 2025-3-28 13:56:24
http://reply.papertrans.cn/27/2686/268543/268543_40.png